Victoria Johnson

Investigators analyzed levels of CXCL10, MMP3, S100A8, ACP5, and CCL2 in patients treated with biologics and methotrexate.

Mease went over research initiatives including the ARGO, AXIS, and STAR studies.

The MTX + HCQ group had a higher, but not statistically significant, incidence rate of TEAEs than the monotherapy group.

Participants in a study in China also experienced comparable safety and immunogenicity.

The rheumatology month in review emphasize's bimekizumab's efficacy in treating PsA and new risk factors and mitigators for developing gout or hyperuricemia.

The biosimilars month in review highlights recent data demonstrating clinical equivalence and efforts to improve their access.

The FDA approved neffy for treating severe allergic reactions in people over 33 kg in August 2024.

Investigators noted that a formal independent validation cohort needs to be developed in order to realize the full potential of the human model.

Patients receiving Humira or Hulio had the highest satisfaction levels across different measures.

The HCPLive August gastroenterology month in review spotlights expansions in gastrointestinal treatment and screening access as well as the newest edition of Qazi Corner.

Investigators identified 6 themes during semistructed interviews that contributed to and described the experience of people with gout.

Researchers identified 2 genes associated with increased risk and 3 associated with decreased risk.

Mease discussed data supporting FDA approval for the indications in Fall 2024.

Those with limited health literacy had higher disease activity and more SLE damage.

Dialysis efficiency was similar between the ULT group and the no ULT group.

Lengths of stay, total cost, and hospital mortality rates were similar between patients with and without rheumatoid arthritis.

Investigators found that 107 metabolites were associated with the incidence of hospitalized gout.

There were no significant differences in the overall incidence of AEs and serious AEs.

Investigators also found that bDMARDs were used more often by patients with early-onset rheumatoid arthritis than by patients with late-onset.

Molybdenum’s antioxidative properties may help reduce systemic inflammation, ROS, and uric acid levels.

Productivity improved in patients with IA after starting treatment.

Other recent research found that having osteoarthritis increased the risk of developing carpal tunnel syndrome.

Rates of adverse events leading to discontinuation were similar between populations of moderate-to-severe psoriasis and psoriatic arthritis.

Higher risk associations also included being a current smoker and socioeconomic deprivation.

Another recent study found that the risk of joint damage and gout flares were most important to patients when considering ULT discontinuation.

More patients also switched from combination therapy to monotherapy at any time in both analyzed database populations.

Around 20% of participants had ultrasound evidence of at least 1 active enthesitis, and 15.7% had ultrasound signs of at least 1 active synovitis at examination.

Each unit increase in TyG index was associated with 40% higher odds of gout.

Adoption rates of infliximab biosimilars only sped up after introduction of a third biosimilar.